Distribution deals allocate commercial work—selling, stocking, installing, training, first-line service—without necessarily transferring ownership of the QMS or the regulatory file. Done well, they are the fastest path to revenue in a new geography. Done poorly, they create silent vigilance gaps, channel conflict, and recall chaos. This page is for manufacturers hunting partners and for distributors hunting SKUs: what to negotiate, what to publish in a teaser, and when distribution is smarter than buying the asset.
A distributor is whoever sits between your legal manufacturer responsibilities and the customer or patient touchpoint. They might take title or act as agent; they might warehouse; they might own account relationships. The label on the business card matters less than whether traceability, training, complaints, recalls, and field corrections have named owners, budgets, and playbooks.
Good agreements read like operating manuals, not just margin schedules: inventory ownership, expiry handling, loaner pools, loaned capital equipment, spare parts, and who pays for vigilance investigations.
One partner leads a defined geography or segment. Use when brand coherence, clinical messaging, and service depth need a single accountable operator. Demand minimum purchase or revenue, marketing investment, and data transparency (sell-through, inventory aging).
Multiple partners or hybrid direct+indirect. Works when segments are cleanly separated (e.g., hospital vs alternate site) or when you are piloting before locking exclusivity. Requires explicit conflict rules and pricing discipline.
Hybrid structures exist: exclusive in one country, non-exclusive in another; exclusive for disposables but not capital; exclusive for clinical specialty but not retail. Spell it out—assumptions become disputes.
Many “distribution” conversations are really OEM supply + partner brand. The manufacturer remains on the hook for batch release and DHF integrity; the partner owns customer-facing brand and sometimes local registration. Change control, batch traceability, and supplier audit rights need explicit language—treat it like a manufacturing agreement with a sales chapter, not a generic dist deal.
If the endgame is still ownership transfer, read acquisitions and map milestones in exit options.
GPO access, contract admin burden, sterile logistics, and whether clinical specialists are required for safe use.
Importer/distributor roles under MDR, vigilance contacts, and post-market surveillance handoffs—often paired with U.S. manufacturing.
Disposable cadence with capital equipment; forecast stability matters for safety stock.
Consumer vigilance patterns, return logistics, and marketing claims tightly bound to labeling and local advertising law.
Channel economics can intersect with healthcare fraud and abuse rules, kickback sensitivities, and transparency reporting depending on jurisdiction and customer type. This is not legal advice—involve counsel when structuring discounts, conversion fees, or anything that looks like paid referrals. Good operators build compliance review into the template, not after the handshake.
Many buyers phrase mandates in ways that overlap distribution and light M&A—read the detail page before assuming they only want equity.
A commercially credible wound-care listing for teams that can expand regional market access faster than the current owner can justify internally.
View details →A practical procedural-kit opportunity for operators that already know how to move sterile disposables through specialist channels.
View details →A mature but under-prioritized ambulatory monitoring line that could become strategically meaningful under a more focused owner.
View details →A rights-led women’s health opportunity suited to partners that already understand specialist office adoption and regional channel buildout.
View details →A strategic-options mandate around a credible decentralized diagnostics platform with stronger upside under a focused scale plan.
View details →Sellers: say whether you offer exclusivity, regions, and revenue share tolerance. Buyers: post geography and channel truthfully to attract aligned OEMs.
These pages cross-link intentionally—follow the path that matches your mandate, then return to the live board when you are ready to act.
Long-form guide: acquisition & distribution mechanics (with regulatory citations)
When the partner cannot cover service geography, inventory turns, or clinical training depth your device needs. Exclusivity without minimums, cure periods, and exit ramps can freeze revenue. Sometimes two disciplined non-exclusive partners beat one mediocre exclusive.
A contract-defined geography (or account segment) where a partner leads commercialization—often with minimum purchase or revenue, marketing spend, and regulatory liaison duties. It is not automatically an acquisition; it can be permanent or a stepping stone with a call option.
The contract must name intake paths, escalation timelines, MDR/reporting responsibilities, and field-action logistics—not assume ‘the manufacturer will handle it.’ Ambiguity here is how distributors and OEMs discover they both thought the other party owned vigilance.
Title, tax, inventory risk, and who books revenue change. Medically, traceability and recall scope still follow facts—your agreement should say who physically controls lots and how quarantine works.